Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
bioMĂ©rieux faces increased volatility ahead of half-year numbers, RBC affirms rating
RBC warns that bioMérieux shares could react with increased volatility ahead of the half-year results on September 4, as an anticipated upgrade to guidance may not materialize. The bank confirms its "Sector Perform" rating with a price target of €125 and sees growth drivers intact over the medium term, but cautions about near-term pressures from weaker segments, currency effects and tariffs. RBC expects Q2 revenue of €973m, a cumulative currency headwind of around 190 basis points for 2024–25 and potential tariff burdens of about 70 basis points. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 1.96bn | - |
| Gross profit | 1.08bn | - |
| Net profit | 226.1m | - |
| EBITDA | 441.2m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €10.92bn |
Number of shares | 117.69m |
52-week high/low | €116.10 - €65.60 |
Dividend yield | 1.05% |
Dividends TTM | €0.98 |
Beta | 0.59 |
P/E ratio | 23.61 |
PEG ratio | 1.02 |
P/B ratio | 2.54 |
P/S ratio | 2.74 |
Company profile
bioMĂ©rieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D MĂ©rieux. bioMĂ©rieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMĂ©rieux S.A. is a subsidiary of Institut MĂ©rieux SA.
| Name | bioMerieux |
| CEO | Pierre Boulud |
| Headquarters | Marcy l'Étoile,
ara France |
| Website | |
| Sector | Health Care |
| Industry | Health Care Technology |
| IPO | 07/07/2004 |
| Employees | 14,894 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | BIM.PA |
Pnk | BMXMF |
Frankfurt | EYWN.F |
DĂĽsseldorf | EYWN.DU |
London | 0RUG.L |
Paris | BIM.PA |
MĂĽnchen | EYWN.MU |
Wien | BIM.VI |
